v3.25.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Research and development expenses $ 13,335,316 $ 9,402,417
Acquired in-process research and development ("IPR&D")   16,217,655
General and administrative expenses 4,314,176 4,144,648
Operating Loss (17,649,492) (29,764,720)
Other (Expense) Income:    
Employee Retention Tax Credit   334,443
Grant income 57,627 42,466
Interest expense (4,138,301) (18,688)
Interest income 361,632 89,673
Change in fair value of derivative liability (313,772)  
Total Other (Expense) Income (4,032,814) 447,894
Net Loss (21,682,306) (29,316,826)
Series A Preferred cash dividend (2,089)  
Deemed dividend on warrant modifications (965,177)  
Net Loss attributable to common stockholders $ (22,649,572) $ (29,316,826)
Net Loss per share, basic $ (1.21) $ (2.47)
Net Loss per share, diluted $ (1.21) $ (2.47)
Weighted-average shares outstanding, basic 18,662,690 11,889,193
Weighted-average shares outstanding, diluted 18,662,690 11,889,193

Source